Syndrome of Inappropriate Anti-Diuretic Hormone Secretion Secondary to Strongyloides stercoralis Infection in an Allogeneic Stem Cell Transplant Patient: A Case Report and Literature Review

Morris, Michele; Diaz, Liege; Goodman, Mark; Pereira, Denise; Fuller, Katherine; García-Buitrago, Mónica; Moshiree, Baharak; Zelaya, S.; Nayer, Ali; Benjamin, Cara L.; Komanduri, Krishna V.

doi:10.1016/j.transproceed.2016.12.012

Cited by 12 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and ranks as the third leading cause of cancer-related deaths, killing more than 600,000 people each year [1, 2]. Previous reports have identified many risk factors, including alcohol use, liver cirrhosis, hepatitis.…”

Section: Introductionmentioning

confidence: 99%

MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

et al. 2019

View full text Add to dashboard Cite

Background CB 2 (cannabinoid receptor 2) agonists have been shown to exert anti-tumor activities in different tumor types. However, there is no study exploring the role of MDA19 (a novel CB 2 agonist) in tumors. In this study we aimed to investigate the effects of MDA19 treatment on HCC cell lines, Hep3B and HepG2 and determine the relevant mechanisms. Results Cell proliferation analysis, including CCK8 and colony formation assays, indicated that MDA19 treatment inhibited HCC cell proliferation in a dose- and time-dependent manner. Flow cytometry suggested that MDA19 induced cell apoptosis and activation of mitochondrial apoptosis pathway. Transwell assay indicated that HCC cell migration and invasion were significantly inhibited by MDA19 treatment. Mechanism investigation suggested that MDA19 induced inactivation of AKT signaling pathway in HCC cells. In addition, we investigated the function of CB 2 receptor in HCC and its role in the anti-tumor activity of MDA19. By searching on Kaplan-Meier plotter ( http://kmplot.com/analysis/ ), we found that HCC patients with high CB 2 expression had a better survival and CB2 expression was significantly associated with gender, clinical stages and race of HCC patients ( P < 0.05). CB 2 inhibited the progression of HCC cells and its knockdown could rescue the growth inhibition induced by MDA19 in HCC. Moreover, the inhibitory effect of MDA19 on AKT signaling pathway was also reversed by CB 2 knockdown. Conclusion Our data suggest that MDA-19 exerts an anti-tumor activity at least partly through inactivation of AKT signaling pathway in HCC. CB 2 functions as a tumor suppressor gene in HCC, and MDA19-induced growth inhibition of HCC cells depends on its binding to CB 2 to activate it. MDA-19 treatment may be a promising strategy for HCC therapy. Reviewer This article was reviewed by Tito Cali, Mohamed Naguib and Bo Chen.

show abstract

Section: Introductionmentioning

confidence: 99%

MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Among all liver cancer cases, the percentage of HCC has reached ~80%–90% and >600,000 people die of it every year. 1 – 3 Previous reports have shown that HCC morbidity is mainly caused by hepatitis B/C virus infection, liver cirrhosis, alcohol addiction and environmental pollution. 4 – 6 There are some inspiring therapies having been designed to treat HCC, such as liver transplantation, sorafenib and percutaneous ablation.…”

Section: Introductionmentioning

confidence: 99%

Downregulation of lncRNA OGFRP1 inhibits hepatocellular carcinoma progression by AKT/mTOR and Wnt/β-catenin signaling pathways

Chen¹,

You²,

Zheng³

et al. 2018

CMAR

View full text Add to dashboard Cite

IntroductionIncreasing evidence demonstrates that long noncoding RNAs (lncRNAs) play important roles in the progression of hepatocellular carcinoma (HCC) by regulating gene expression. However, the identification of functional lncRNAs in HCC remains insufficient. Our study aimed to investigate the function of lncRNA OGFRP1, which has not been functionally researched before, in Hep3B and HepG2 cells.MethodslncRNA OGFRP1 in HCC cells was down-regulated by using RNAi technology. Quantitative real-time polymerase chain reaction was used to determine the mRNA expression of lncRNA OGFRP1. Cell proliferation was examined by CCK8 and clone formation assays. Cell cycle and apoptosis were analyzed by flow cytometry. Cell migration and invasion were assessed by using Scratch assay and transwell assay, respectively. Protein expression of signaling pathways was determined by using Western blot.ResultsCell proliferation of Hep3B was significantly inhibited by down-regulation of lncRNA OGFRP1 (P<0.05). Moreover, siOGFRP1 transfection induced Hep3B cell cycle arrest and apoptosis by regulating the expression of related proteins. Cell migration and invasion of Hep3B were also significantly inhibited by down-regulation of lncRNA OGFRP1. Wnt/β-catenin signaling pathway, involved in epithelial–mesenchymal transition (EMT), was inactivated by lncRNA OGFRP1 downregulation, including decreased expression of Wnt3a, β-catenin, N-cadherin and vimentin and increased expression of E-cadherin. We also found that the inhibitory effect of lncRNA OGFRP1 knockdown on Hep3B was mediated by the AKT/mTOR signaling pathway and IGF-1, an AKT signaling activator, could rescue the cellular phenotype. However, knockdown of lncRNA OGFRP1 did not influence cell proliferation, migration and invasion in HepG2 cells.ConclusionWe found that downregulation of lncRNA OGFRP1 suppressed the proliferation and EMT of HCC Hep3B cells through AKT and Wnt/β-catenin signaling pathways. However, lncRNA OGFRP1 exhibited a differentiated function in different HCC cell lines, which required further study in the future.

show abstract

“…To the best of our knowledge, only 8 cases [48–55] of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and Strongyloides infection have been reported in the literature (Table 2). However, there is extensive involvement of the lung parenchyma or central nervous system seen in most of these cases.…”

Section: Discussionmentioning

confidence: 99%

Anemia, intractable vomiting, chronic diarrhea, and syndrome of inappropriate antidiuretic secretion

Tariq

Kamal²,

Reddy³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

Syndrome of Inappropriate Anti-Diuretic Hormone Secretion Secondary to Strongyloides stercoralis Infection in an Allogeneic Stem Cell Transplant Patient: A Case Report and Literature Review

Cited by 12 publications

References 13 publications

MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

Downregulation of lncRNA OGFRP1 inhibits hepatocellular carcinoma progression by AKT/mTOR and Wnt/β-catenin signaling pathways

Anemia, intractable vomiting, chronic diarrhea, and syndrome of inappropriate antidiuretic secretion

Contact Info

Product

Resources

About

Syndrome of Inappropriate Anti-Diuretic Hormone Secretion Secondary to Strongyloides stercoralis Infection in an Allogeneic Stem Cell Transplant Patient: A Case Report and Literature Review

Cited by 12 publications

References 13 publications

MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

Downregulation of lncRNA OGFRP1 inhibits hepatocellular carcinoma progression by AKT/mTOR and Wnt/&beta;-catenin signaling pathways

Anemia, intractable vomiting, chronic diarrhea, and syndrome of inappropriate antidiuretic secretion

Contact Info

Product

Resources

About

Downregulation of lncRNA OGFRP1 inhibits hepatocellular carcinoma progression by AKT/mTOR and Wnt/β-catenin signaling pathways